TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05583)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A subject must be 12 years of age or older, of either sex, and of any race.~* A subject must have at least a 2-year history of SAR which exacerbates during the study season.~* A subject must have a positive skin prick test response to an appropriate seasonal allergen at Visit 1.~* A subject must be clinically symptomatic at the Screening and Baseline Visits.~Exclusion Criteria:~* A subject with a history of severe local reaction(s) or anaphylaxis to skin testing.~* A subject who has had an upper respiratory tract or sinus infection that required antibiotic therapy without at least a 14-day washout prior to the Screening Visit, or who has had a viral upper respiratory infection within 7 days prior to the Screening Visit.~* A subject who has used any drug in an investigational protocol in the 30 days prior to the Screening Visit.~* A subject who is participating in any other clinical study.~* A subject who is part of the staff personnel directly involved with this study.~* A subject who is a family member (parent, spouse, or sibling) of the investigational study staff.~* A female subject who is breast-feeding, pregnant, or intends to become pregnant.~* A subject previously randomized into this study.~* A subject who has a family member (parent, spouse, or sibling) currently enrolled in this study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Mometasone furoate nasal spray 200 mcg QD (once per day)
- Arm 2 (Type: PLACEBO_COMPARATOR): Matching placebo nasal spray

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Dexmedetomidine on Recovery Profiles of Elderly Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-II~* Age \> 65~* Elective surgery~Exclusion Criteria:~* Patients with severe heart disease with New York Heart Association class \> III~* Patients with severe arrhythmia~* Patients with uncontrolled hypertension or hypotension~* Patients with hemodynamic unstably~* Patients with hypersensitivity with drugs~* Patients with cognitive deficiency, dementia, or delirium~* Patients with hepatic or renal compromise~* Patients with infective disease

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: PLACEBO_COMPARATOR): General anesthesia with sevoflurane. Infusion of normal saline during surgery. Administer rocuronium 0.8 mg/kg for induction.
- Group 2 (Type: PLACEBO_COMPARATOR): General anesthesia with propofol and remifentanil. (Total intravenous anesthesia) Infusion of normal saline during surgery. Administer rocuronium 0.8 mg/kg for induction.
- Group 3 (Type: EXPERIMENTAL): General anesthesia with sevoflurane. Infusion of dexmedetomidine (0.4 ug/kg/hr) during anesthesia. Administer rocuronium 0.8 mg/kg for induction.
- Group 4 (Type: EXPERIMENTAL): General anesthesia with propofol and remifentanil. (Total intravenous anesthesia) Infusion of dexmedetomidine (0.4 ug/kg/hr) during surgery. Administer rocuronium 0.8 mg/kg for induction.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 80~* If female, postmenopausal or surgically sterilized~* Liver metastases from colorectal carcinoma scheduled for a CT/MRI-guided single-fraction interstitial HDR brachytherapy~* Non-cirrhotic liver~* Life expectancy longer than 6 months~* willing and able to undergo all study procedures~* Having voluntarily provided written and fully informed consent~Exclusion Criteria:~* Women who are pregnant, lactating or who are of childbearing potential~* Liver cirrhosis~* Hepatitis B~* Hepatitis C~* Patients being clinically unstable~* Uncooperative, in the investigator's opinion~* Having been previously enrolled in this study~* Participating in another therapy-modulating clinical trial~* Contraindication for MRI~* Contraindication or hypersensitivity to one or more components of Gd-EOB-DTPA, Enoxaparin, Ursodeoxycholic acid and/or Pentoxifylline~* Any prior irradiation therapy of the liver~* Close affiliation with the investigational site; e.g. a close relative of the investigator~* Severe coronary artery disease~* Autoimmune diseases~* Acute bacterial endocarditis~* Active major bleedings and high rish of uncontrolled haemorrhage~* Patients with severe or moderate renal impairment (GFR below 60 mL/min/1.73 m2 according to the MDRD or Cockroft-Gault formula, calculated from a creatinine value obtained within 1 week before each planned Primovist-enhanced MR examination)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Medication group with patients receiving the study medication according to the study protocol for 8 weeks after HDR brachytherapy.
- Group B (Type: NO_INTERVENTION): Comparison group with patients receiving the standard therapy of HDR brachytherapy without the study specific medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects with community-acquired pneumonia requiring:~* initial hospitalization or treatment in an emergency room or urgent care setting~* infection requiring initial treatment with IV antimicrobial~Exclusion Criteria:~* Community-acquired pneumonia suitable for outpatient therapy with an oral antimicrobial agent~* Respiratory tract infections not due to community-acquired bacterial pathogens~* Infections resistant to ceftriaxone~* Any condition requiring concomitant systemic corticosteroids~* History of any hypersensitivity or allergic reaction to any ß-lactam antimicrobial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ceftaroline fosamil for injection (Type: EXPERIMENTAL): Ceftaroline fosamil was administered in two consecutive 300 mg IV infusions over 30 minutes, every 12 hours (q12h).
- IV Ceftriaxone (Type: ACTIVE_COMPARATOR): Ceftriaxone was administered as a 1-g IV infusion over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes for 12 months or longer, hereof the last 3 months with injection based therapies~* Current treatment with any basal insulin (e.g. insulin glargine, insulin detemir, NPH insulin) using one or two daily injections and with three or more daily meal-time insulin injections (e.g. insulin aspart, insulin lispro, insulin glulisine, human insulin) used as bolus insulin therapy~* HbA1c maximum 10.0 % by central laboratory analysis~* Body Mass Index (BMI) below or equal to 35.0 kg/m\^2~* Ability to self-manage insulin therapy as assessed by confirmation (verbal confirmation at screening visit) of a changed insulin dose in the preceding two months prior to screening~* Ability and willingness to adhere to the protocol including performance of self measured plasma glucose (SMPG) profiles and self adjustment of insulin doses~Exclusion Criteria:~* Use within the last 3 months prior to Visit 1 of any antidiabetic glucose lowering drug other than insulin~* Cardiovascular disease, within the last 6 months prior to visit 1, defined as: stroke; decompensated heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty~* Uncontrolled treated/ untreated severe hypertension (systolic blood pressure above or equal to 180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure above or equal to 100 mmHg)~* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements~* Cancer and medical history of cancer (except basal cell skin cancer or squamous cell skin cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Flex + insulin aspart (Type: EXPERIMENTAL): None
- Fixed + insulin aspart (Type: EXPERIMENTAL): None
- IGlar + insulin aspart (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study in in Vitro Fertilisation (IVF) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women undergoing ovarian stimulation for IVF with the following characteristics:~  * Able and willing to sign the Patient Consent Form and adhere to the study visitation schedule~ * \>18 and \<40 years old~ * BMI between 18 and 30 kg/m2~ * less than 3 previously completed IVF cycles (i.e. completed cycle = egg recovery)~ * basal FSH \<10 IU/L and E2 \<80 pg/ml (\~290 pmol/l)~ * Within 12 months of the beginning of the study, uterine cavity consistent with expected normal function as assessed through transvaginal ultrasound, hysterosalpingogram, sonohysterogram or hysteroscopic examination~ * Successful down-regulation performed with a standard GnRH-Agonist long protocol (Criteria for successful down-regulation: endometrial thickness \< 7mm or serum E2 level \<50 pg/ml (\~185 pmol/l).~Exclusion Criteria:~* age \<18 and \>40 years~* primary ovarian failure or women known as poor responders (i.e. requiring more than 225 IU of hMG as a starting dose in previous treatment cycles or having less than 3 oocytes retrieved, or with a pre-ovulatory E2 serum concentration \<500pg/ml (\~1800 pmol/l))~* PCOS~* one or both ovaries inaccessible for oocyte retrieval~* ovarian cysts \>10 mm~* hydrosalpinx that have not been surgically removed or ligated;~* stage 3 or 4 endometriosis~* oocyte donation~* implantation of previously frozen embryos~* patients affected by pathologies associated with any contraindication of being pregnant~* hypersensitivity to the study medication~* abnormal bleeding of undetermined origin~* uncontrolled thyroid or adrenal dysfunction~* neoplasias~* severe impairment of renal and/or hepatic function~* use of concomitant medications that might interfere with study evaluations (e.g. non-study hormonal medications, prostaglandin inhibitors, psychotropic agents)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- hMG-IBSA (Type: EXPERIMENTAL): New hMG preparation.
- Menopur (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metronidazole Pharmacokinetics (PK) in Premature Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age \<32 weeks at the time of enrollment.~* Postnatal age \<91 days at the time of enrollment.~* Sufficient venous access to permit administration of study medication.~* Infant suspected to have a serious infection and from whom a blood culture has been obtained within 96 hours of study entry.~Exclusion Criteria:~* History of anaphylaxis to metronidazole or other nitroimidazole derivatives (e.g., tinidazole).~* Previous exposure to metronidazole in the week prior to study.~* Previous participation in the study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 90 Days
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Intravenous metronidazole loading dose 15 mg/kg followed by 7.5 mg/kg every 12-24 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Biopsy-proven Hodgkin's disease, subclassified according to the Rye system Clinical Stages IA, IEA, IIA, and IIEA according to modified Ann Arbor system Staging laparotomy not allowed Completely resected disease allowed Residual disease, if present, must be bidimensionally measurable No mediastinal mass greater than 1/3 the maximum chest diameter No infradiaphragmatic presentation No pericardial E lesions (small pericardial effusions in the absence of nodular pericardial disease allowed) Concurrent registration on protocol SWOG-9208 (quality-of-life study) required unless patient does not understand or read English~PATIENT CHARACTERISTICS: Age: 16 and over Performance status: SWOG 0-2 Hematopoietic: AGC at least 2,000 Platelets within normal limits Hepatic: Bilirubin within normal limits Renal: Creatinine within normal limits Cardiovascular: LVEF normal No serious EKG abnormality Pulmonary: No serious pulmonary condition Other: No serious medical condition other than Hodgkin's disease No known AIDS or HIV-associated complex No second malignancy within 5 years except: Adequately treated nonmelanomatous skin cancer Adequately treated in situ carcinoma of the cervix No pregnant or lactating women Adequate contraception required of fertile patients Blood/body fluid analyses to determine eligibility completed within 14 days prior to registration; imaging studies for tumor measurement completed within 28 days prior to registration; screening exams other than blood/body fluid analyses, and imaging studies of nonmeasurable disease or uninvolved organs completed within 42 days prior to registration~PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy Chemotherapy: No prior chemotherapy for any reason Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy for any reason Surgery: No staging laparotomy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nodal RT (Type: EXPERIMENTAL): subtotal nodal irradiation will consist of mantle and periaortic/spleen fields treated sequentially. Total dose 3600-4000 cGy over 20 fractions.
- Chemotherapy + Nodal RT (Type: EXPERIMENTAL): 3 cycles (28 days each) of chemotherapy (doxorubicin 25 mg/m\^2 on days 1 and 15, vinblastine 6 mg/m\^2 on days 1 and 15). Four weeks after last cycle, subtotal nodal irradiation (total dose 3600-4000 cGy over 20 fractions) will be given as described for the Nodal RT arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: mVIP (Use of mHealth Technology for Supporting Symptom Management in Underserved Persons Living With HIV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosed with HIV/AIDS~2. Over the age of 18 years~3. Able to provide written informed consent~4. Able to communicate in English~5. Health literacy level of marginal or inadequate (as measured by the Newest Vital Sign (NVS): total score of 3 or lower)~6. Report at least 2 HIV related adverse symptoms in the past week~7. Owner of a smart phone/tablet.~Exclusion Criteria:~1. Inability to communicate in English~2. Documented diagnosis of dementia~3. Pregnancy~4. Unable to understand consent procedure~5. Self-reporting no adverse symptoms within the past week. (HIV-related symptoms include: anxiety, constipation, cough, depression, diarrhea, dizziness, fever, forgetfulness, fatigue, nausea, night sweats, neuropathy, shortness of breath, dermatitis, swelling of arms, hand, legs, feet, insomnia, weight loss, oral thrush, and vaginal itching, burning and discharge)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mVIP group (Type: EXPERIMENTAL): This group will receive targeted symptom strategies via a Health Management App developed from the UCSF symptom management manual based on the symptoms that they report. This is the intervention app group.
- Attention Control Group (Type: PLACEBO_COMPARATOR): This group will received an app without symptom strategies, pre-loaded on their smartphones. This is the control app group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Environmental Treatment for Seasonal Affective Disorder (SAD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects meet DSM-IV criteria for major depressive episodes with a seasonal pattern, winter type.~Exclusion Criteria:~* Significant suicidal risk~* Serious medical illness~* Pregnancy~* Other DSM-IV diagnoses~* Taking mood altering medication~* May not travel to a sunny destination during study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- LED phototherapy device (Type: EXPERIMENTAL): Litebook treatment devices: LED phototherapy device, used for 30 min before 8 am
- Inactivated Negative Ion Generator (Type: PLACEBO_COMPARATOR): Equivalent exposure to inactivated negative ion generator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect Of Acetazolamide On Altitude Related Illness In Patients With Respiratory Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients, age 18-75 yrs.~* COPD diagnosed according to GOLD, FEV1 40-80% predicted, SpO2 ≥92% at 750 m.~* Born, raised and currently living at low altitude (\<800m).~* Written informed consent.~Exclusion Criteria:~* COPD exacerbation, very severe COPD with hypoxemia at low altitude (FEV1/FVC \<0.7, FEV1 \<40% predicted, oxygen saturation on room air \<92% at 750 m).~* Comorbidities such as uncontrolled cardiovascular disease, i.e., unstable systemic arterial hypertension, coronary artery disease; previous stroke; OSA; pneumothorax in the last 2 months.~* Internal, neurologic, rheumatologic or psychiatric disease including current heavy smoking (\>20 cigarettes per day)~* Known renal failure or allergy to acetazolamide and other sulfonamides

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ACETAZOLAMIDE oral capsule (Type: ACTIVE_COMPARATOR): Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
- PLACEBO oral capsule (Type: PLACEBO_COMPARATOR): Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post-marketing Observational Study in Subjects With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants with ongoing adalimumab treatment who completed at least Month 3 (Visit 5) of NCT00448383 (Study M02-497) and who had subsequently been prescribed adalimumab according to the Summary of Product Characteristics (SmPC).~* Participants must have been willing to consent to data being collected and provided to Abbott.~Exclusion Criteria:~· Participants with contraindications according to the SmPC.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: None): RA patients in treatment with commercial adalimumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete